Cheryl Cathey, CEO & Co-founder
Cheryl is an experienced executive and entrepreneur. She’s worked in the diagnostics and life science industries for over 25 years in startups and leading diagnostic companies. She has a strong technical and business development background and broad knowledge of the diagnostic and life science industries. She received a B.S. in Chemical Engineering from the University of Colorado and M.S and Ph.D. degrees in Chemical Engineering from Stanford University.
John Wiencke, CTO & Co-founder
John is a Professor in the Department of Neurological Surgery at UCSF and holds an endowed chair in Neuro-Oncology. He’s an expert in the genetic epidemiology of glioma and lung cancer, tumor genetics and DNA methylation as an immune biomarker. He received a B.S. in Biology, an M.S. in Environmental Health and a Ph.D. in Laboratory Medicine and Pathology, all from the University of Minnesota.
Brock C. Christensen, Advisor & Co-founder
Brock is a Professor of Epidemiology and Molecular and Systems Biology at Dartmouth. He received a B.S. in Medical Microbiology & Immunology from the University of Wisconsin, and a P.D. in Biological Sciences in Public Health from Harvard University. His molecular epidemiologic research is primarily cancer focused and aims to develop clinically useful tools that benefit patients and clinicians. He currently co-leads the Cancer Population Sciences Research Program at Dartmouth Cancer Center.
Karl Kelsey, Advisor & Co-founder
Karl is a Professor of Epidemiology and Laboratory Medicine & Pathology at Brown. His research has focused on numerous aspects of exposure-related cancer and chronic disease, specifically with an interest in further understanding the epigenetics of this inter-related biology. He’s also a pioneer in the team approach to “dense data” science. He received a B.A. in Physics and an M.D. in Medicine from the University of Minnesota, and an M.O.H in Occupational Health from Harvard University.
Lucas Salas, Advisor & Co-Founder
The broad goal of Lucas’s research is to investigate how cell heterogeneity impacts human health and disease, with an emphasis on how genetic, environmental and lifestyle factors model the human epigenome and therefore the cell plasticity. Dr. Salas’ laboratory studies how some key epigenetic mechanisms (DNA methylation, DNA hydroxymethylation, and miRNA alterations) affect gene expression and cancer outcomes, including how the immune cells are altered in this disease.